Inotrem granted access to priority medicines scheme (PRIME) for its lead compound MOTREM™ in the treatment of septic shock.
November 15, 2017
Paris, November 15, 2017. Inotrem S.A., a biotechnology company specialized in the control of acute inflammatory syndromes, today announced that the European Medicines Agency (EMA)